Cell & Gene Therapy Market by Therapy Type (Cell Therapy, Gene Therapy), Delivery Method (Intramuscular, Intravenous), Therapeutic Areas, Application, End User - Global Forecast 2025-2032
Description
The Cell & Gene Therapy Market was valued at USD 16.65 billion in 2024 and is projected to grow to USD 19.47 billion in 2025, with a CAGR of 19.95%, reaching USD 71.38 billion by 2032.
Concise orientation to the scientific progress and practical strategic considerations shaping development, manufacturing, and commercialization decisions in cell and gene therapy
The cell and gene therapy field is advancing from pioneering science to increasingly sophisticated clinical practice and industrial deployment. Recent technological innovations in vector design, cell engineering, and delivery platforms have expanded the scope of addressable conditions while simultaneously reshaping how organizations approach development, manufacturing, and commercialization. As clinical pipelines mature, stakeholders face a new set of strategic imperatives that include managing supply chain complexity, aligning regulatory strategies across jurisdictions, and building operational capabilities that support long-term program sustainability.
This introduction situates the reader at the intersection of scientific progress and market-driven decision making. It emphasizes how translational milestones translate into organizational choices about therapeutic focus, manufacturing investments, and collaborative models. By framing current momentum alongside persistent challenges such as scalability, cold-chain logistics, and workforce specialization, this section prepares executives and technical leaders to interpret subsequent analyses with a clear sense of priority and risk. The objective is to provide a concise orientation that highlights both opportunity and the practical constraints that must be navigated to realize durable patient impact.
Evolving technological, regulatory, and commercial paradigms that are redefining how therapies are developed, manufactured, and monetized across the ecosystem
The landscape of cell and gene therapy is undergoing transformative shifts driven by converging forces in technology, regulation, and commercial models. Advances in cell editing and vector engineering are enabling more precise therapeutic modalities, while improvements in automated manufacturing and modular facility design are lowering operational friction. Regulatory agencies are also adapting, introducing accelerated pathways and guidance frameworks that reflect the unique risk–benefit profiles of these therapies, which in turn affects development timelines and go‑to‑market strategies.
Concurrently, commercialization dynamics are evolving as payers, providers, and manufacturers experiment with outcomes-based contracting, installment pricing, and risk-sharing arrangements to address affordability and access. Strategic partnerships are increasingly prevalent, spanning academia, biotech startups, and large pharmaceutical companies, and catalyzing rapid knowledge transfer. These shifts necessitate new organizational capabilities, including integrated supply chain management, advanced analytics for patient identification, and cross-functional regulatory teams that can execute complex global filings. Taken together, these trends point to an ecosystem that is more interconnected and more strategically nuanced than in prior eras.
Analysis of how recent trade policy adjustments are reshaping sourcing, manufacturing location choices, and supply chain resilience strategies for advanced therapies
Recent tariff measures introduced by the United States have introduced additional complexity into global supply chains that support cell and gene therapy programs. Manufacturers that rely on imported reagents, consumables, specialized equipment, or raw materials must now contend with higher landed costs and potential disruptions to procurement strategies. These dynamics have prompted many organizations to reassess sourcing strategies, explore supplier diversification, and accelerate qualification of alternative materials to preserve program timelines.
Beyond cost implications, tariffs can influence decisions about geographic placement of manufacturing capacity and the structure of strategic partnerships. Organizations sensitive to supply chain volatility are evaluating nearshoring or onshoring options to reduce exposure to trade policy shifts, while others are strengthening inventory planning and contractual protections with suppliers. At the same time, procurement teams are increasingly engaging with regulatory and quality functions to ensure that alternative sourcing pathways meet compliance requirements. The cumulative effect of these trade policy changes is a renewed emphasis on supply chain resilience as a core strategic capability for organizations that are developing or commercializing cell and gene therapies.
Deep segmentation analysis connecting therapy types, delivery routes, clinical indications, application focus, and end-user environments to strategic development choices
A nuanced segmentation framework reveals how therapeutic focus, delivery methods, clinical indications, application context, and end-user environments drive divergent needs and strategic choices across the sector. When therapies are classified by type, distinctions between cell therapies and gene therapies create fundamentally different development and manufacturing requirements; within cell therapies, stem cell approaches and T cell approaches each follow distinct technical and regulatory pathways, and further subtypes such as hematopoietic and mesenchymal stem cell paradigms or CAR T and TCR-based T cell constructs introduce specialized vector, potency, and handling considerations. Gene therapies also split into ex vivo and in vivo approaches, with each route demanding tailored delivery, safety monitoring, and long-term follow up strategies.
Delivery method influences clinical operations and patient pathways: intramuscular administration favors certain therapeutic concepts and outpatient models, whereas intravenous delivery often necessitates different infrastructure and monitoring capabilities. Therapeutic areas further differentiate program design and stakeholder engagement, as cardiovascular and metabolic disorder programs require integration with chronic care pathways, neurological disorder programs demand specialized outcome measures and long-term efficacy assessment, oncology programs balance acute treatment paradigms and complex manufacturing for hematological malignancies and solid tumors, and ophthalmology programs present unique localized delivery and safety profiles. The distinction between clinical applications and research and development underscores divergent resourcing and regulatory approaches, with clinical applications oriented toward disease prevention or treatment and R&D emphasizing discovery, translational validation, and early human testing. Finally, end users shape adoption dynamics: academic and research institutes, including private research labs and universities, drive innovation and early clinical translation, while hospitals and clinics focus on scale-up, clinical delivery, and integration into standard-of-care pathways. Understanding these layered segmentations allows organizations to align technical investments, go‑to‑market strategies, and partnership models with the specific demands of their chosen subdomains.
Comparative regional dynamics and strategic considerations across the Americas, Europe Middle East & Africa, and Asia-Pacific that shape trials, approvals, and commercialization
Regional dynamics exert a powerful influence on development pathways, regulatory strategies, and commercialization approaches. In the Americas, a concentration of innovative clinical programs, strong venture funding ecosystems, and large tertiary care centers supports rapid translation from bench to bedside, while payer landscapes and reimbursement models shape market access approaches. Europe, the Middle East & Africa present a diverse regulatory and healthcare environment where centralized approval mechanisms can coexist with regional variability in adoption and reimbursement, requiring nuanced market entry planning and stakeholder engagement across multiple jurisdictions. The Asia-Pacific region is characterized by a combination of rapidly expanding clinical capacity, government-led initiatives to accelerate biotechnology, and an active manufacturing base that can support both local and global supply needs.
These regional distinctions inform decisions on where to site clinical trials, how to structure regulatory submissions, and which commercial partnerships to prioritize. Stakeholders must weigh the benefits of local clinical expertise and manufacturing capabilities against considerations such as regulatory harmonization, intellectual property frameworks, and the availability of specialized clinical infrastructure. Strategic leaders increasingly adopt a regionally informed playbook that sequences activities to capitalize on local strengths while managing cross-border complexities, thereby enabling scalable and resilient program execution.
How industry incumbents, specialized service providers, and research institutions are structuring partnerships, capability investments, and platform differentiation strategies
Competitive and collaborative dynamics among leading organizations, specialized contract providers, and academic centers are defining the operational contours of the sector. Established pharmaceutical companies are investing in in‑house capabilities and partnering with nimble biotech firms to access novel platforms, while contract development and manufacturing organizations expand service portfolios to include cell processing, viral vector production, and cold-chain logistics. Academic and research institutes remain pivotal as sources of innovation and early-stage clinical validation, often entering partnerships to translate discoveries into industrial programs.
Across this landscape, companies differentiate through investments in automated manufacturing, platform technologies that enable multiple therapeutic programs, and data systems that support process analytics and quality by design. Strategic alliances and licensing deals continue to accelerate technology transfer and market entry, with many organizations prioritizing partnerships that shorten time to clinic and mitigate technical risk. Observing these behaviors, stakeholders should focus on building capabilities that complement external relationships, such as strong program management, regulatory expertise, and commercial readiness functions that together enable rapid scaling when scientific proof points emerge.
Practical and prioritized actions for executives to strengthen supply resilience, scale manufacturing, align regulatory strategy, and accelerate market access for advanced therapies
Leaders across industry and academia should pursue a set of actionable strategies that translate insight into measurable advances. First, strengthen supply chain and procurement governance by diversifying suppliers, qualifying alternative inputs, and implementing inventory strategies that reduce vulnerability to trade policy shifts and single-source dependencies. Second, invest in modular and scalable manufacturing solutions combined with automation and digital process control to lower per-batch variability and accelerate capacity expansion when needed. Third, align regulatory and clinical strategies early by engaging with authorities, designing robust long-term follow-up plans, and incorporating real-world evidence frameworks to support value arguments.
Additionally, cultivate dynamic partnership models that balance in‑house capability development with targeted collaborations, leveraging academic centers for discovery and specialized CDMOs for reliable scale-up. Prioritize workforce development programs that build cross-disciplinary expertise in cell processing, biomanufacturing, and regulatory science. Finally, embed payer and health system engagement into late-stage development planning to ensure that evidence generation supports access pathways. These actionable moves will help organizations translate technical advances into durable clinical programs and commercially viable therapies.
Transparent and evidence-driven approach combining expert interviews, regulatory guidance analysis, and literature synthesis to derive actionable strategic insights
The research methodology underpinning this analysis integrates qualitative synthesis, stakeholder interviews, and cross‑disciplinary literature review to produce actionable and contextually grounded insights. Primary inputs include structured dialogues with clinical researchers, manufacturing experts, regulatory advisors, and commercial leaders to capture on‑the-ground perspectives and emerging operational challenges. Secondary inputs encompass peer-reviewed publications, regulatory guidance documents, technology assessments, and publicly disclosed corporate activities that provide technical and strategic context.
Analysis relied on triangulation across sources to validate themes and identify areas of convergence and tension. Emphasis was placed on identifying practical implications for decision makers rather than on quantitative projections. The methodological approach prioritized transparency in assumptions, careful differentiation between established trends and early signals, and clear articulation of the evidence base supporting each conclusion. This combination of primary engagement and rigorous secondary analysis ensures that recommendations are actionable and attuned to real-world constraints.
Strategic synthesis of scientific potential and operational imperatives that executives must reconcile to deliver scalable and patient-centric cell and gene therapies
In conclusion, the cell and gene therapy ecosystem is entering a phase characterized by technological maturation and heightened operational complexity. Scientific advances continue to expand therapeutic possibilities, but realizing patient impact at scale now depends equally on organizational capabilities in manufacturing, supply chain management, regulatory navigation, and payer engagement. Stakeholders that build resilience into their supply networks, invest in scalable manufacturing platforms, and adopt collaborative partnership models will be better positioned to translate scientific breakthroughs into accessible therapies.
Moving forward, strategic clarity about therapeutic focus, deliberate segmentation-driven planning, and proactive engagement with regulators and payers will distinguish successful programs. The field’s evolution presents an opportunity to reimagine clinical pathways, commercial models, and collaborative frameworks in ways that accelerate patient access while managing risk. Executives who couple scientific ambition with rigorous operational planning and strategic partnerships will unlock the full potential of cell and gene therapies.
Note: PDF & Excel + Online Access - 1 Year
Concise orientation to the scientific progress and practical strategic considerations shaping development, manufacturing, and commercialization decisions in cell and gene therapy
The cell and gene therapy field is advancing from pioneering science to increasingly sophisticated clinical practice and industrial deployment. Recent technological innovations in vector design, cell engineering, and delivery platforms have expanded the scope of addressable conditions while simultaneously reshaping how organizations approach development, manufacturing, and commercialization. As clinical pipelines mature, stakeholders face a new set of strategic imperatives that include managing supply chain complexity, aligning regulatory strategies across jurisdictions, and building operational capabilities that support long-term program sustainability.
This introduction situates the reader at the intersection of scientific progress and market-driven decision making. It emphasizes how translational milestones translate into organizational choices about therapeutic focus, manufacturing investments, and collaborative models. By framing current momentum alongside persistent challenges such as scalability, cold-chain logistics, and workforce specialization, this section prepares executives and technical leaders to interpret subsequent analyses with a clear sense of priority and risk. The objective is to provide a concise orientation that highlights both opportunity and the practical constraints that must be navigated to realize durable patient impact.
Evolving technological, regulatory, and commercial paradigms that are redefining how therapies are developed, manufactured, and monetized across the ecosystem
The landscape of cell and gene therapy is undergoing transformative shifts driven by converging forces in technology, regulation, and commercial models. Advances in cell editing and vector engineering are enabling more precise therapeutic modalities, while improvements in automated manufacturing and modular facility design are lowering operational friction. Regulatory agencies are also adapting, introducing accelerated pathways and guidance frameworks that reflect the unique risk–benefit profiles of these therapies, which in turn affects development timelines and go‑to‑market strategies.
Concurrently, commercialization dynamics are evolving as payers, providers, and manufacturers experiment with outcomes-based contracting, installment pricing, and risk-sharing arrangements to address affordability and access. Strategic partnerships are increasingly prevalent, spanning academia, biotech startups, and large pharmaceutical companies, and catalyzing rapid knowledge transfer. These shifts necessitate new organizational capabilities, including integrated supply chain management, advanced analytics for patient identification, and cross-functional regulatory teams that can execute complex global filings. Taken together, these trends point to an ecosystem that is more interconnected and more strategically nuanced than in prior eras.
Analysis of how recent trade policy adjustments are reshaping sourcing, manufacturing location choices, and supply chain resilience strategies for advanced therapies
Recent tariff measures introduced by the United States have introduced additional complexity into global supply chains that support cell and gene therapy programs. Manufacturers that rely on imported reagents, consumables, specialized equipment, or raw materials must now contend with higher landed costs and potential disruptions to procurement strategies. These dynamics have prompted many organizations to reassess sourcing strategies, explore supplier diversification, and accelerate qualification of alternative materials to preserve program timelines.
Beyond cost implications, tariffs can influence decisions about geographic placement of manufacturing capacity and the structure of strategic partnerships. Organizations sensitive to supply chain volatility are evaluating nearshoring or onshoring options to reduce exposure to trade policy shifts, while others are strengthening inventory planning and contractual protections with suppliers. At the same time, procurement teams are increasingly engaging with regulatory and quality functions to ensure that alternative sourcing pathways meet compliance requirements. The cumulative effect of these trade policy changes is a renewed emphasis on supply chain resilience as a core strategic capability for organizations that are developing or commercializing cell and gene therapies.
Deep segmentation analysis connecting therapy types, delivery routes, clinical indications, application focus, and end-user environments to strategic development choices
A nuanced segmentation framework reveals how therapeutic focus, delivery methods, clinical indications, application context, and end-user environments drive divergent needs and strategic choices across the sector. When therapies are classified by type, distinctions between cell therapies and gene therapies create fundamentally different development and manufacturing requirements; within cell therapies, stem cell approaches and T cell approaches each follow distinct technical and regulatory pathways, and further subtypes such as hematopoietic and mesenchymal stem cell paradigms or CAR T and TCR-based T cell constructs introduce specialized vector, potency, and handling considerations. Gene therapies also split into ex vivo and in vivo approaches, with each route demanding tailored delivery, safety monitoring, and long-term follow up strategies.
Delivery method influences clinical operations and patient pathways: intramuscular administration favors certain therapeutic concepts and outpatient models, whereas intravenous delivery often necessitates different infrastructure and monitoring capabilities. Therapeutic areas further differentiate program design and stakeholder engagement, as cardiovascular and metabolic disorder programs require integration with chronic care pathways, neurological disorder programs demand specialized outcome measures and long-term efficacy assessment, oncology programs balance acute treatment paradigms and complex manufacturing for hematological malignancies and solid tumors, and ophthalmology programs present unique localized delivery and safety profiles. The distinction between clinical applications and research and development underscores divergent resourcing and regulatory approaches, with clinical applications oriented toward disease prevention or treatment and R&D emphasizing discovery, translational validation, and early human testing. Finally, end users shape adoption dynamics: academic and research institutes, including private research labs and universities, drive innovation and early clinical translation, while hospitals and clinics focus on scale-up, clinical delivery, and integration into standard-of-care pathways. Understanding these layered segmentations allows organizations to align technical investments, go‑to‑market strategies, and partnership models with the specific demands of their chosen subdomains.
Comparative regional dynamics and strategic considerations across the Americas, Europe Middle East & Africa, and Asia-Pacific that shape trials, approvals, and commercialization
Regional dynamics exert a powerful influence on development pathways, regulatory strategies, and commercialization approaches. In the Americas, a concentration of innovative clinical programs, strong venture funding ecosystems, and large tertiary care centers supports rapid translation from bench to bedside, while payer landscapes and reimbursement models shape market access approaches. Europe, the Middle East & Africa present a diverse regulatory and healthcare environment where centralized approval mechanisms can coexist with regional variability in adoption and reimbursement, requiring nuanced market entry planning and stakeholder engagement across multiple jurisdictions. The Asia-Pacific region is characterized by a combination of rapidly expanding clinical capacity, government-led initiatives to accelerate biotechnology, and an active manufacturing base that can support both local and global supply needs.
These regional distinctions inform decisions on where to site clinical trials, how to structure regulatory submissions, and which commercial partnerships to prioritize. Stakeholders must weigh the benefits of local clinical expertise and manufacturing capabilities against considerations such as regulatory harmonization, intellectual property frameworks, and the availability of specialized clinical infrastructure. Strategic leaders increasingly adopt a regionally informed playbook that sequences activities to capitalize on local strengths while managing cross-border complexities, thereby enabling scalable and resilient program execution.
How industry incumbents, specialized service providers, and research institutions are structuring partnerships, capability investments, and platform differentiation strategies
Competitive and collaborative dynamics among leading organizations, specialized contract providers, and academic centers are defining the operational contours of the sector. Established pharmaceutical companies are investing in in‑house capabilities and partnering with nimble biotech firms to access novel platforms, while contract development and manufacturing organizations expand service portfolios to include cell processing, viral vector production, and cold-chain logistics. Academic and research institutes remain pivotal as sources of innovation and early-stage clinical validation, often entering partnerships to translate discoveries into industrial programs.
Across this landscape, companies differentiate through investments in automated manufacturing, platform technologies that enable multiple therapeutic programs, and data systems that support process analytics and quality by design. Strategic alliances and licensing deals continue to accelerate technology transfer and market entry, with many organizations prioritizing partnerships that shorten time to clinic and mitigate technical risk. Observing these behaviors, stakeholders should focus on building capabilities that complement external relationships, such as strong program management, regulatory expertise, and commercial readiness functions that together enable rapid scaling when scientific proof points emerge.
Practical and prioritized actions for executives to strengthen supply resilience, scale manufacturing, align regulatory strategy, and accelerate market access for advanced therapies
Leaders across industry and academia should pursue a set of actionable strategies that translate insight into measurable advances. First, strengthen supply chain and procurement governance by diversifying suppliers, qualifying alternative inputs, and implementing inventory strategies that reduce vulnerability to trade policy shifts and single-source dependencies. Second, invest in modular and scalable manufacturing solutions combined with automation and digital process control to lower per-batch variability and accelerate capacity expansion when needed. Third, align regulatory and clinical strategies early by engaging with authorities, designing robust long-term follow-up plans, and incorporating real-world evidence frameworks to support value arguments.
Additionally, cultivate dynamic partnership models that balance in‑house capability development with targeted collaborations, leveraging academic centers for discovery and specialized CDMOs for reliable scale-up. Prioritize workforce development programs that build cross-disciplinary expertise in cell processing, biomanufacturing, and regulatory science. Finally, embed payer and health system engagement into late-stage development planning to ensure that evidence generation supports access pathways. These actionable moves will help organizations translate technical advances into durable clinical programs and commercially viable therapies.
Transparent and evidence-driven approach combining expert interviews, regulatory guidance analysis, and literature synthesis to derive actionable strategic insights
The research methodology underpinning this analysis integrates qualitative synthesis, stakeholder interviews, and cross‑disciplinary literature review to produce actionable and contextually grounded insights. Primary inputs include structured dialogues with clinical researchers, manufacturing experts, regulatory advisors, and commercial leaders to capture on‑the-ground perspectives and emerging operational challenges. Secondary inputs encompass peer-reviewed publications, regulatory guidance documents, technology assessments, and publicly disclosed corporate activities that provide technical and strategic context.
Analysis relied on triangulation across sources to validate themes and identify areas of convergence and tension. Emphasis was placed on identifying practical implications for decision makers rather than on quantitative projections. The methodological approach prioritized transparency in assumptions, careful differentiation between established trends and early signals, and clear articulation of the evidence base supporting each conclusion. This combination of primary engagement and rigorous secondary analysis ensures that recommendations are actionable and attuned to real-world constraints.
Strategic synthesis of scientific potential and operational imperatives that executives must reconcile to deliver scalable and patient-centric cell and gene therapies
In conclusion, the cell and gene therapy ecosystem is entering a phase characterized by technological maturation and heightened operational complexity. Scientific advances continue to expand therapeutic possibilities, but realizing patient impact at scale now depends equally on organizational capabilities in manufacturing, supply chain management, regulatory navigation, and payer engagement. Stakeholders that build resilience into their supply networks, invest in scalable manufacturing platforms, and adopt collaborative partnership models will be better positioned to translate scientific breakthroughs into accessible therapies.
Moving forward, strategic clarity about therapeutic focus, deliberate segmentation-driven planning, and proactive engagement with regulators and payers will distinguish successful programs. The field’s evolution presents an opportunity to reimagine clinical pathways, commercial models, and collaborative frameworks in ways that accelerate patient access while managing risk. Executives who couple scientific ambition with rigorous operational planning and strategic partnerships will unlock the full potential of cell and gene therapies.
Note: PDF & Excel + Online Access - 1 Year
Table of Contents
196 Pages
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency
- 1.5. Language
- 1.6. Stakeholders
- 2. Research Methodology
- 3. Executive Summary
- 4. Market Overview
- 5. Market Insights
- 5.1. Expansion of allogeneic CAR T-cell therapies targeting solid tumors through universal donor platforms
- 5.2. Integration of CRISPR-based gene editing in in vivo therapies for rare genetic disorders to improve safety and efficacy
- 5.3. Adoption of automated closed-system manufacturing to reduce costs and scale production of personalized cell therapies
- 5.4. Development of next-generation AAV vector platforms to enhance tissue specificity and decrease immunogenicity in gene therapies
- 5.5. Implementation of decentralized point-of-care manufacturing models for on-site production of autologous cell therapies
- 5.6. Emergence of multi-specific and armored CAR T-cell constructs to overcome tumor microenvironment immunosuppression
- 5.7. Strategic partnerships between biotech firms and CDMOs to accelerate clinical development and commercialization of cell therapies
- 5.8. Regulatory harmonization efforts to streamline global approval pathways and accelerate patient access to gene treatments
- 5.9. Application of artificial intelligence and digital twins for process analytics and optimization in cell therapy manufacturing
- 5.10. Investment in supply chain innovations, including cryopreservation and cold chain logistics, to ensure cell product viability worldwide
- 6. Cumulative Impact of United States Tariffs 2025
- 7. Cumulative Impact of Artificial Intelligence 2025
- 8. Cell & Gene Therapy Market, by Therapy Type
- 8.1. Cell Therapy
- 8.1.1. Stem Cell Therapies
- 8.1.1.1. Hematopoietic Stem Cell Therapies
- 8.1.1.2. Mesenchymal Stem Cell Therapies
- 8.1.2. T Cell Therapy
- 8.1.2.1. CAR T Cell Therapy
- 8.1.2.2. T Cell Receptor (TCR)-based
- 8.2. Gene Therapy
- 8.2.1. Ex Vivo Gene Therapy
- 8.2.2. In Vivo Gene Therapy
- 9. Cell & Gene Therapy Market, by Delivery Method
- 9.1. Intramuscular
- 9.2. Intravenous
- 10. Cell & Gene Therapy Market, by Therapeutic Areas
- 10.1. Cardiovascular
- 10.1.1. Congestive Heart Failure
- 10.1.2. Ischemic Heart Disease
- 10.2. Metabolic Disorders
- 10.2.1. Diabetes
- 10.2.2. Obesity
- 10.3. Neurological Disorders
- 10.3.1. Alzheimer's Disease
- 10.3.2. Huntington's Disease
- 10.3.3. Multiple Sclerosis
- 10.3.4. Parkinson's Disease
- 10.3.5. Spinal Cord Injuries
- 10.4. Oncology
- 10.4.1. Hematological Malignancies
- 10.4.2. Lymphomas
- 10.4.3. Solid Tumors
- 10.5. Ophthalmology
- 11. Cell & Gene Therapy Market, by Application
- 11.1. Clinical Applications
- 11.1.1. Disease Prevention
- 11.1.2. Disease Treatment
- 11.2. Research & Development
- 12. Cell & Gene Therapy Market, by End User
- 12.1. Academic & Research Institutes
- 12.1.1. Private Research Labs
- 12.1.2. Universities
- 12.2. Hospitals & Clinics
- 13. Cell & Gene Therapy Market, by Region
- 13.1. Americas
- 13.1.1. North America
- 13.1.2. Latin America
- 13.2. Europe, Middle East & Africa
- 13.2.1. Europe
- 13.2.2. Middle East
- 13.2.3. Africa
- 13.3. Asia-Pacific
- 14. Cell & Gene Therapy Market, by Group
- 14.1. ASEAN
- 14.2. GCC
- 14.3. European Union
- 14.4. BRICS
- 14.5. G7
- 14.6. NATO
- 15. Cell & Gene Therapy Market, by Country
- 15.1. United States
- 15.2. Canada
- 15.3. Mexico
- 15.4. Brazil
- 15.5. United Kingdom
- 15.6. Germany
- 15.7. France
- 15.8. Russia
- 15.9. Italy
- 15.10. Spain
- 15.11. China
- 15.12. India
- 15.13. Japan
- 15.14. Australia
- 15.15. South Korea
- 16. Competitive Landscape
- 16.1. Market Share Analysis, 2024
- 16.2. FPNV Positioning Matrix, 2024
- 16.3. Competitive Analysis
- 16.3.1. AbbVie Inc.
- 16.3.2. Abeona Therapeutics Inc.
- 16.3.3. Adaptimmune Therapeutics PLC
- 16.3.4. AGC Inc.
- 16.3.5. Alnylam Pharmaceuticals, Inc.
- 16.3.6. American Gene Technologies Inc.
- 16.3.7. Amgen Inc.
- 16.3.8. AnGes, Inc
- 16.3.9. Astellas Pharma Inc.
- 16.3.10. Becton, Dickinson and Company
- 16.3.11. Biogen Inc.
- 16.3.12. Bluebird Bio, Inc.
- 16.3.13. BridgeBio Pharma, Inc.
- 16.3.14. Bristol-Myers Squibb Company
- 16.3.15. C.H. Boehringer Sohn AG & Co. KG
- 16.3.16. Cellectis SA
- 16.3.17. CRISPR Therapeutics AG
- 16.3.18. F. Hoffmann-La Roche AG
- 16.3.19. Gilead Sciences, Inc.
- 16.3.20. Intellia Therapeutics, Inc.
- 16.3.21. Ionis Pharmaceuticals, Inc.
- 16.3.22. Johnson & Johnson Services Inc.
- 16.3.23. Kyowa Kirin Co., Ltd.
- 16.3.24. Merck KGaA
- 16.3.25. Moderna, Inc.
- 16.3.26. Mustang Bio, Inc.
- 16.3.27. Novartis AG
- 16.3.28. Novo Nordisk A/S
- 16.3.29. Pfizer, Inc.
- 16.3.30. REGENXBIO Inc.
- 16.3.31. Sangamo Therapeutics, Inc.
- 16.3.32. Sarepta Therapeutics, Inc.
- 16.3.33. Shoreline Biosciences
- 16.3.34. Sibiono GeneTech Co. Ltd.
- 16.3.35. Syncona Limited
- 16.3.36. Thermo Fisher Scientific Inc.
- 16.3.37. Vertex Pharmaceuticals Incorporated
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
